These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

393 related articles for article (PubMed ID: 27526117)

  • 1. Effectiveness of Pneumococcal Conjugate Vaccines (PCV7 and PCV13) against Invasive Pneumococcal Disease among Children under Two Years of Age in Germany.
    van der Linden M; Falkenhorst G; Perniciaro S; Fitzner C; Imöhl M
    PLoS One; 2016; 11(8):e0161257. PubMed ID: 27526117
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term Impact of a "3 + 0" Schedule for 7- and 13-Valent Pneumococcal Conjugate Vaccines on Invasive Pneumococcal Disease in Australia, 2002-2014.
    Jayasinghe S; Menzies R; Chiu C; Toms C; Blyth CC; Krause V; McIntyre P
    Clin Infect Dis; 2017 Jan; 64(2):175-183. PubMed ID: 27986682
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effectiveness of a 3 + 0 pneumococcal conjugate vaccine schedule against invasive pneumococcal disease among a birth cohort of 1.4 million children in Australia.
    Gidding HF; McCallum L; Fathima P; Moore HC; Snelling TL; Blyth CC; Jayasinghe S; Giele C; de Klerk N; Andrews RM; McIntyre PB;
    Vaccine; 2018 May; 36(19):2650-2656. PubMed ID: 29627233
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effectiveness of the seven-valent and thirteen-valent pneumococcal conjugate vaccines in England: The indirect cohort design, 2006-2018.
    Andrews N; Kent A; Amin-Chowdhury Z; Sheppard C; Fry N; Ramsay M; Ladhani SN
    Vaccine; 2019 Jul; 37(32):4491-4498. PubMed ID: 31272872
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of the pneumococcal conjugate vaccines on invasive pneumococcal disease in France, 2001-2012.
    Lepoutre A; Varon E; Georges S; Dorléans F; Janoir C; Gutmann L; Lévy-Bruhl D; ;
    Vaccine; 2015 Jan; 33(2):359-66. PubMed ID: 25448105
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prompt effect of replacing the 7-valent pneumococcal conjugate vaccine with the 13-valent vaccine on the epidemiology of invasive pneumococcal disease in Norway.
    Steens A; Bergsaker MA; Aaberge IS; Rønning K; Vestrheim DF
    Vaccine; 2013 Dec; 31(52):6232-8. PubMed ID: 24176490
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Regional variations in serotype distribution and vaccination status in children under six years of age with invasive pneumococcal disease in Germany.
    Perniciaro S; Imöhl M; Fitzner C; van der Linden M
    PLoS One; 2019; 14(1):e0210278. PubMed ID: 30625215
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effectiveness of the new serotypes in the 13-valent pneumococcal conjugate vaccine.
    Miller E; Andrews NJ; Waight PA; Slack MP; George RC
    Vaccine; 2011 Nov; 29(49):9127-31. PubMed ID: 21983361
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevention of pneumococcal disease among infants and children - use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine - recommendations of the Advisory Committee on Immunization Practices (ACIP).
    Nuorti JP; Whitney CG;
    MMWR Recomm Rep; 2010 Dec; 59(RR-11):1-18. PubMed ID: 21150868
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effectiveness of three pneumococcal conjugate vaccines to prevent invasive pneumococcal disease in Quebec, Canada.
    Deceuninck G; De Serres G; Boulianne N; Lefebvre B; De Wals P
    Vaccine; 2015 May; 33(23):2684-9. PubMed ID: 25887086
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effectiveness of Pneumococcal Conjugate Vaccines of Different Valences Against Invasive Pneumococcal Disease Among Children in Taiwan: A Nationwide Study.
    Su WJ; Lo HY; Chang CH; Chang LY; Chiu CH; Lee PI; Lu CY; Hsieh YC; Lai MS; Lin TY
    Pediatr Infect Dis J; 2016 Apr; 35(4):e124-33. PubMed ID: 26974752
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Incidence of invasive pneumococcal disease before and during an era of use of three different pneumococcal conjugate vaccines in Quebec.
    De Wals P; Lefebvre B; Deceuninck G; Longtin J
    Vaccine; 2018 Jan; 36(3):421-426. PubMed ID: 29224962
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pediatric invasive pneumococcal disease caused by vaccine serotypes following the introduction of conjugate vaccination in Denmark.
    Harboe ZB; Valentiner-Branth P; Ingels H; Rasmussen JN; Andersen PH; Bjerre CC; Goldblatt D; Ashton L; Haston M; Konradsen HB; Lambertsen L;
    PLoS One; 2013; 8(1):e51460. PubMed ID: 23365635
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effectiveness of the 13-valent pneumococcal conjugate vaccine in preventing invasive pneumococcal disease in children aged 7-59 months. A matched case-control study.
    Domínguez Á; Ciruela P; Hernández S; García-García JJ; Soldevila N; Izquierdo C; Moraga-Llop F; Díaz A; F de Sevilla M; González-Peris S; Campins M; Uriona S; Martínez-Osorio J; Solé-Ribalta A; Codina G; Esteva C; Planes AM; Muñoz-Almagro C; Salleras L
    PLoS One; 2017; 12(8):e0183191. PubMed ID: 28806737
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characteristics and Serotype Distribution of Childhood Cases of Invasive Pneumococcal Disease Following Pneumococcal Conjugate Vaccination in England and Wales, 2006-2014.
    Oligbu G; Collins S; Andrews N; Sheppard CL; Fry NK; Slack MPE; Borrow R; Ladhani SN
    Clin Infect Dis; 2017 Oct; 65(7):1191-1198. PubMed ID: 29309553
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predicted serotype-specific effectiveness of pneumococcal conjugate vaccines V114 and PCV20 against invasive pneumococcal disease in children.
    Ryman J; Sachs JR; Yee KL; Banniettis N; Weaver J; Weiss T
    Expert Rev Vaccines; 2024; 23(1):60-68. PubMed ID: 38073483
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effectiveness of 13-valent pneumococcal conjugate vaccine for prevention of invasive pneumococcal disease among children in the United States between 2010 and 2019: An indirect cohort study.
    Andrejko KL; Gierke R; Rowlands JV; Rosen JB; Thomas A; Landis ZQ; Rosales M; Petit S; Schaffner W; Holtzman C; Barnes M; Farley MM; Harrison LH; McGee L; Chochua S; Verani JR; Cohen AL; Pilishvili T; Kobayashi M
    Vaccine; 2024 Jun; 42(16):3555-3563. PubMed ID: 38704263
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of Infant Pneumococcal Conjugate Vaccination on Serotype Distribution in Invasive Pneumococcal Disease among Children and Adults in Germany.
    van der Linden M; Falkenhorst G; Perniciaro S; Imöhl M
    PLoS One; 2015; 10(7):e0131494. PubMed ID: 26132078
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vaccine effectiveness of the 7-valent and 13-valent pneumococcal conjugate vaccines in Canada: An IMPACT study.
    Ricketson LJ; Bettinger JA; Sadarangani M; Halperin SA; Kellner JD;
    Vaccine; 2022 Apr; 40(19):2733-2740. PubMed ID: 35351324
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Early impact of sequential introduction of 7-valent and 13-valent pneumococcal conjugate vaccine on IPD in Israeli children <5 years: an active prospective nationwide surveillance.
    Ben-Shimol S; Greenberg D; Givon-Lavi N; Schlesinger Y; Somekh E; Aviner S; Miron D; Dagan R
    Vaccine; 2014 Jun; 32(27):3452-9. PubMed ID: 24690148
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.